Crux, a new benefits platform, announced its public launch today after securing $6.5 million in pre-seed funding from venture studio Red Cell Partners, aiming to expand transparent and affordable access to quality-of-life (QoL) medications for employees in the United States.

Established in 2024, Crux positions itself as the first benefits platform designed to partner with pharmaceutical manufacturers and employers of all sizes. It facilitates access to high-demand QoL therapies—medications and treatments that support overall health and well-being but are often not covered by traditional insurance. The platform achieves this by combining employers’ non-taxed subsidies with employee contributions, bringing these typically expensive treatments within financial reach.

U.

S.-based employers interested in Crux’s offerings can join a waitlist at getcrux.com to learn about upcoming medications. Employers will be able to finalize their configuration choices in January, with the first prescriptions scheduled for delivery in or before February 2026.

The Crux platform is designed to provide employers with access to QoL medications at significantly discounted rates, free from markups or hidden fees. Key features include simplified access without the need for coupons, rebates, or complex reimbursement processes. Employers gain a turn-key healthcare purchasing experience, allowing them to set their own contribution levels, configure the member experience, and select care-support vendors. The system enables employers to pay only for benefits utilized, avoiding upfront or recurring costs, and to make non-taxed contributions to reduce out-of-pocket expenses for beneficiaries. Additionally, organizations can join at any time, unrestricted by open enrollment periods, while employees benefit from free, optional engagement tools, educational resources, and expedited next-day delivery on all orders.

Chip Nash, Co-founder and CEO of Crux, stated, “The economics of integrated pharmacy benefits have been working against U.

S. employers and beneficiaries for far too long, keeping breakthrough medications out of reach for most Americans. It’s time for that to change.” Nash added that Crux offers significant value by providing employers with a unique opportunity to address employee demand for these medications through thoughtful, employer-sponsored programs that feature improved economic terms, flexibility, and greater choice for employees regarding their health and wellbeing.

The Crux leadership team brings extensive experience in scaling employer benefits programs. Grant Verstandig, Co-founder and Executive Chairman, previously founded and served as CEO of Rally Health, a consumer-centric digital health company acquired by UnitedHealth Group in 2017. Following the acquisition, Verstandig was UnitedHealth Group’s Chief Digital Officer and has since founded multiple companies in healthcare and defense. Chip Nash, Co-founder and CEO, spent over two decades in digital healthcare and product leadership, joining Rally Health as employee #3 and helping it become a leading incentives platform in healthcare. Naimish Patel, Co-founder, was employee #1 at Rally Health and later served as Vice President and General Manager of Enterprise Solutions at Optum, a division of UnitedHealth Group.

Grant Verstandig, who is also the founder and CEO of Red Cell Partners, commented on the genesis of Crux, stating, “After scaling Rally to over $1 billion in revenue, I learned that the hardest problems in healthcare aren’t clinical, they’re structural.” He highlighted the soaring popularity of medications like GLP-1s for various conditions and noted that while employers recognize the demand, existing infrastructure hinders access. Red Cell incubated Crux to create a functional system.

Verstandig further elaborated on Red Cell’s investment philosophy, explaining that Crux exemplifies their thesis: addressing a substantial market failure where an estimated 160 million Americans lack access to desired quality-of-life medications. He emphasized the team’s proven track record from Rally, aiming to replicate that success with Crux to create a significant opportunity in a sector where incumbents have not met market needs.